1. At a Glance – The Pharma Veteran Goes MedTech Shopping
₹65,256 crore market cap. ₹5,458 stock price. Stock P/E of 27.2. ROCE at 20.4%. ROE at 19.4%. Q3 FY26 revenue of ₹3,737 crore and PAT of ₹653 crore. Operating margin at a healthy 22%.
And just when you thought this was a regular Indian pharma story, Alkem went ahead and signed a binding term sheet to acquire 51–55% in Occlutech Holding AG for €180.70 million (₹19,516 million at EUR/INR 108).
Yes. The anti-infectives king just decided to plug holes in people’s hearts — literally.
Three-month return? -4.27%.
One-year return? 15.6%.
Dividend yield? 0.82%.
The market seems confused. Is Alkem a steady domestic formulation cash machine? Or a global MedTech aspirant?
And more importantly… are we watching a cautious expansion — or the beginning of a new growth chapter?
Let’s dissect.
2. Introduction – From PAN-D to PFO Devices
Alkem is not your flashy biotech disruptor. It’s the solid, old-school, disciplined pharmaceutical machine.
Founded decades ago, it built its empire in anti-infectives — the segment where Indian doctors prescribe like it’s Diwali sweets season. Today, it holds a 4.1% share of the Indian domestic formulation market as of 9M FY25 and ranks #5 in India.
#1 in anti-infectives.
#3 in gastro.
#3 in pain.
#2 in vitamins.
That’s not luck. That’s distribution muscle.
With 12,500+ field force, 9 central warehouses, 75+ depots, and 8,400+ stockists, Alkem can probably deliver antibiotics to a village before Swiggy delivers biryani.
But here’s the twist.
Instead of just milking its domestic cash cow, the company is stepping into MedTech — orthopedics and cardiovascular devices — through Alkem MedTech and a majority stake in Occlutech.
Pharma companies going into devices isn’t common. Different science. Different margins. Different regulation.
So why now? And why this big?
Because when pharma growth slows, you either innovate… or stagnate.
Which one is Alkem choosing?
3. Business Model – WTF Do They Even Do?
Let’s simplify this for the “I read annual reports only on Sundays” investor.
A) Domestic Pharma (70% of revenue)
This is the cash engine.
They manufacture branded generics across:
- Anti-infectives
- Gastrointestinal
- Pain management
- Vitamins & minerals
- Chronic therapies (neuro, cardiac, diabetic)
They have 6 brands in the top 100 IPM list and 17 brands in top 300.
Their bread-and-butter? Doctors writing prescriptions that say PAN-D and CLAVAM like it’s muscle memory.
Recently launched: Generic Empagliflozin “Empanorm” — priced 80% lower than
